Showing results (81-90 of 182) with videos related to
Sort By:
Pageof 19
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.Endocrine-Related Cancer|June 30, 2016
Myeloid neoplasms after chemotherapy and PRRT: myth and realityLisa Bodei, Irvin M Modlin, Markus Luster, et al.The Oncologist|August 31, 2018
Assessment of NETest Clinical Utility in a U.S. Registry-Based StudyEric Liu, Scott Paulson, Anthony Gulati, et al.Neuroendocrinology|February 9, 2013
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumorsMaddalena Sansovini, Stefano Severi, Alice Ambrosetti, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2018
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclidesDaria Handkiewicz-Junak, Thorsten D Poeppel, Lisa Bodei, et al.The Journal of Clinical Endocrinology and Metabolism|September 15, 2020
Approach to the Treatment of a Patient with an Aggressive Pituitary TumorAndrew L Lin, Mark T A Donoghue, Sharon L Wardlaw, et al.Journal of Clinical Medicine|July 3, 2019
A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene MutationAgnieszka Kolasinska-Ćwikła, Mariola Pęczkowska, Jarosław B Ćwikła, et al.European Journal of Endocrinology|August 14, 2014
GEPNETs update: Radionuclide therapy in neuroendocrine tumorsWouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2008
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.Pageof 19